944 related articles for article (PubMed ID: 21525024)
1. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
[TBL] [Abstract][Full Text] [Related]
2. The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital.
Mirza HC; Sancak B; Gür D
Microb Drug Resist; 2015 Oct; 21(5):537-44. PubMed ID: 25919019
[TBL] [Abstract][Full Text] [Related]
3. Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center.
Lin SY; Chen TC; Chen FJ; Chen YH; Lin YI; Siu LK; Lu PL
J Microbiol Immunol Infect; 2012 Dec; 45(6):435-41. PubMed ID: 22749725
[TBL] [Abstract][Full Text] [Related]
4. Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals.
Sader HS; Jones RN; Rossi KL; Rybak MJ
J Antimicrob Chemother; 2009 Nov; 64(5):1024-8. PubMed ID: 19744978
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.
Huang SH; Chen YC; Chuang YC; Chiu SK; Fung CP; Lu PL; Wang LS; Wu TL; Wang JT
J Microbiol Immunol Infect; 2016 Oct; 49(5):701-707. PubMed ID: 26320398
[TBL] [Abstract][Full Text] [Related]
6. Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey.
Sancak B; Yagci S; Gür D; Gülay Z; Ogunc D; Söyletir G; Yalcin AN; Dündar DO; Topçu AW; Aksit F; Usluer G; Ozakin C; Akalin H; Hayran M; Korten V
BMC Infect Dis; 2013 Dec; 13():583. PubMed ID: 24325260
[TBL] [Abstract][Full Text] [Related]
7. High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients.
Wang JL; Lai CH; Lin HH; Chen WF; Shih YC; Hung CH
Int J Antimicrob Agents; 2013 Nov; 42(5):390-4. PubMed ID: 24041465
[TBL] [Abstract][Full Text] [Related]
8. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections.
Hsu DI; Hidayat LK; Quist R; Hindler J; Karlsson A; Yusof A; Wong-Beringer A
Int J Antimicrob Agents; 2008 Nov; 32(5):378-85. PubMed ID: 18701261
[TBL] [Abstract][Full Text] [Related]
9. Presence of both heterogeneous vancomycin-intermediate resistance and β-lactam antibiotic-induced vancomycin resistance phenotypes is associated with the outcome in methicillin-resistant Staphylococcus aureus bloodstream infection.
Takata T; Miyazaki M; Futo M; Hara S; Shiotsuka S; Kamimura H; Yoshimura H; Matsunaga A; Nishida T; Ishikura H; Ishikawa T; Tamura K; Tsuji BT
Scand J Infect Dis; 2013 Mar; 45(3):203-12. PubMed ID: 23113753
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the clinical features, bacterial genotypes and outcomes of patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S. aureus.
Park KH; Kim ES; Kim HS; Park SJ; Bang KM; Park HJ; Park SY; Moon SM; Chong YP; Kim SH; Lee SO; Choi SH; Jeong JY; Kim MN; Woo JH; Kim YS
J Antimicrob Chemother; 2012 Aug; 67(8):1843-9. PubMed ID: 22535621
[TBL] [Abstract][Full Text] [Related]
11. [Investigation of reduced vancomycin susceptibility in methicillin-resistant staphylococci].
Kuşcu F; Oztürk DB; Gürbüz Y; Tütüncü EE; Sencan I; Gül S
Mikrobiyol Bul; 2011 Apr; 45(2):248-57. PubMed ID: 21644067
[TBL] [Abstract][Full Text] [Related]
12. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
Hegde SS; Skinner R; Lewis SR; Krause KM; Blais J; Benton BM
J Antimicrob Chemother; 2010 Apr; 65(4):725-8. PubMed ID: 20139142
[TBL] [Abstract][Full Text] [Related]
13. Screening for Intermediately Vancomycin-Susceptible and Vancomycin-Heteroresistant Staphylococcus aureus by Use of Vancomycin-Supplemented Brain Heart Infusion Agar Biplates: Defining Growth Interpretation Criteria Based on Gold Standard Confirmation.
Khatib R; Riederer K; Sharma M; Shemes S; Iyer SP; Szpunar S
J Clin Microbiol; 2015 Nov; 53(11):3543-6. PubMed ID: 26311860
[TBL] [Abstract][Full Text] [Related]
14. Nationwide surveillance study of vancomycin intermediate Staphylococcus aureus strains in Korean hospitals from 2001 to 2006.
Chung G; Cha J; Han S; Jang H; Lee K; Yoo J; Yoo J; Kim H; Eun S; Kim B; Park O; Lee Ys
J Microbiol Biotechnol; 2010 Mar; 20(3):637-42. PubMed ID: 20372039
[TBL] [Abstract][Full Text] [Related]
15. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
Steinkraus G; White R; Friedrich L
J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693
[TBL] [Abstract][Full Text] [Related]
16. Heteroresistance to glycopeptides in Italian meticillin-resistant Staphylococcus aureus (MRSA) isolates.
Campanile F; Borbone S; Perez M; Bongiorno D; Cafiso V; Bertuccio T; Purrello S; Nicolosi D; Scuderi C; Stefani S
Int J Antimicrob Agents; 2010 Nov; 36(5):415-9. PubMed ID: 20727722
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Microbiological Characteristics of Heteroresistant and Vancomycin-Intermediate Staphylococcus aureus from Bloodstream Infections in a Brazilian Teaching Hospital.
da Costa TM; Morgado PG; Cavalcante FS; Damasco AP; Nouér SA; Dos Santos KR
PLoS One; 2016; 11(8):e0160506. PubMed ID: 27575698
[TBL] [Abstract][Full Text] [Related]
18. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years.
Musta AC; Riederer K; Shemes S; Chase P; Jose J; Johnson LB; Khatib R
J Clin Microbiol; 2009 Jun; 47(6):1640-4. PubMed ID: 19369444
[TBL] [Abstract][Full Text] [Related]
19. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia.
Walraven CJ; North MS; Marr-Lyon L; Deming P; Sakoulas G; Mercier RC
J Antimicrob Chemother; 2011 Oct; 66(10):2386-92. PubMed ID: 21775337
[TBL] [Abstract][Full Text] [Related]
20. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets.
Kullar R; Davis SL; Levine DP; Rybak MJ
Clin Infect Dis; 2011 Apr; 52(8):975-81. PubMed ID: 21460309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
